Myelodysplastic syndrome overview

Seminars in Hematology

Volumn 39, Issue 3 SUPPL. 2, 2002, Pages 18-25

  Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEFEROXAMINE MESYLATE; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; MELPHALAN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; ANTINEOPLASTIC AGENT; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

ACUTE LEUKEMIA; BLEEDING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; INFECTION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; DRUG ANTAGONISM; MORTALITY; PATHOLOGY; PROGNOSIS;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; FARNESYLTRANSTRANSFERASE; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0036655766     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.35981     Document Type: Article

References (75)

1. Myelodysplastic syndrome
2. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases
3. Evolving treatment options of myelodysplastic syndromes
4. International scoring system for evaluating prognosis in myelodysplastic syndromes
5. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: The cause-effect relationship
6. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes
7. Myelodysplastic syndromes in the elderly
8. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis
9. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
10. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes
11. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
12. Proposals for the classification of the myelodysplastic syndromes
13. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
14. The preleukemic syndrome. I. Clinical and hematological findings
15. Clinical course of myelodysplastic syndromes
16. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes
17. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes
18. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases
19. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients
20. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis
21. Infection in the myelodysplastic syndromes
22. Myelodysplastic syndromes: A scoring system with prognostic significance
23. Myelodysplastic syndromes: Pathogenesis, diagnosis and treatment
24. Myelodysplastic syndromes. Medscape®
25. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies
26. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome
27. Pilot study of low-dose interleukin-11 in patients with bone marrow failure
28. Therapeutic efficacy of danazol in myelodysplastic syndromes
29. Danazol therapy in myelodysplasia
30. Refractory anaemia with excess of myeloblasts in the bone marrow: A clinical trial of androgens in 90 patients
31. Refractory anemia with excess of blast cells: Prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients
32. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes
33. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
34. Azacitadine in myelodysplastic syndromes: CALGB studies 8421 and 8921
35. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
36. A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia
37. The role of low-dose chemotherapy in myelodysplastic syndromes
38. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: A pilot study
39. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes
40. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
41. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
42. High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens
43. Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis
44. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission
45. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
46. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
47. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
48. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey
49. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome
50. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders
51. All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome
52. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes
53. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
54. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
55. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
56. Poor response rate to a continuous schedule of amifostine therapy for 'low/intermediate risk' myelodysplastic patients
57. Low-dose melphalan induces favourable responses in elderly patients with highrisk myelodysplastic syndromes or secondary acute myeloid leukaemia
58. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
59. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B
60. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
61. Thalidomide for the treatment of patients with myelodysplastic syndromes
62. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome
63. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyl-transferase inhibitor-induced apoptosis
64. 1 block in p 53 wild type tumor cells
65. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
66. Ras protein farnesyl-transferase: A strategic target for anticancer therapeutic development
67. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R 115777 in vivo and in vitro
68. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
69. Effects of farnesyl transferase inhibitor R115777 on hematopoiesis, leukemic cell proliferation, and signaling through the mitogen-activated protein kinase (MAPK) pathway
70. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
71. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome
72. Phase II study of R115777, a farnesyltransferase inhibitor, in patients with myelodysplastic syndrome